FXYD domain containing ion transport regulator 3Genealiases: MAT8 · PLML
Q-omics provides the consensus-scored FXYD3 profile across patient tissues and cancer cell-line models. FXYD3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FXYD3 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FXYD3 RNA expression shows 13,535 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where FXYD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FXYD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FXYD3 survival associations across molecular data types. FXYD3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FXYD3 RNA expression–survival associations across cancer types. High FXYD3 expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in UVM, DLBC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FXYD3 RNA expression.
This table summarizes FXYD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FXYD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FXYD3 shows lower tumor expression in KIRC, KIRP, COAD, KICH and LUAD and higher tumor expression in BLCA. The KIRC box plot shows higher FXYD3 RNA expression in normal versus tumor tissue (log2 FC = −1.960, t-test p < 0.001).
This table shows molecular features associated with FXYD3 in patient tissues and cancer cell lines. In patient samples, FXYD3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FXYD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
